Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SPINT1
REST API REST API
Homo sapiens
SPINT1 is differentially expressed in 272 experiments: 167 organism parts: prostate, lung, ... (165 more);, 216 disease states: normal, prostate carcinoma, ... (214 more);, 89 cell types 592 cell lines 44 compound treatments and 75 other conditions.
Synonyms MANSC2, HAI
Orthologs Spint1 (Rattus norvegicus)   Q2KJJ7_BOVIN (Bos taurus)   ENSCING00000008877 (Ciona intestinalis)   Spint1 (Mus musculus)   SPINT1 (Gallus gallus)   spint1a (Danio rerio)   CG6495 (Drosophila melanogaster)   spint1b (Danio rerio)   spint1 (Xenopus laevis)   SPINT1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, serine-type endopeptidase inhibitor activity, peptidase inhibitor activity, extracellular region, membrane fraction, extracellular matrix organization, branching involved in embryonic placenta morphogenesis, placenta blood vessel development, embryonic placenta development
InterPro Term MANSC_N, MANSC, Prot_inh_Kunz-m, LDrepeatLR_classA_rpt
UniProt Accession O43278, F5H877
Search EB-eye ENSG00000166145
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-62, E-MTAB-37, E-MEXP-440
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT20
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
586 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
2
E-MEXP-1600, E-AFMX-5, E-MTAB-24
macrophage
1
2
E-GEOD-3982, E-GEOD-360, E-GEOD-22373
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD34+
1
E-AFMX-5
adipose tissue-derived stem cell
1
E-MEXP-872
hematopoietic stem cell
1
E-MEXP-872
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-GEOD-3678, ... (52 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
prostate carcinoma
1
4
E-MTAB-62, E-MTAB-37, E-GEOD-7307, E-GEOD-3868, E-MEXP-2034 ... (5 experiments)
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-MTAB-37, E-MTAB-62
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-2379
210 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
TGF
1
E-GEOD-15205
HMB-PP (phosphoantigen)
1
E-MEXP-1601
hydrogen peroxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
hemin
1
E-GEOD-1036
5-aza-2'-deoxycytidine
3
1
E-GEOD-5230
38 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2191, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-19665, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-MTAB-108

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-GEOD-18736, E-TABM-868, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-GEOD-22278, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.503 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM